Submissions for variant CYP2C9*11

gnomAD frequency: 0.00738  dbSNP: rs28371685

Total submissions: 5

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Medical Genetics Summaries	RCV000787934	SCV000926953	drug response	Flurbiprofen response	2019-02-11	criteria provided, single submitter	curation	The dose of flurbiprofen should be reduced in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) to avoid abnormally high plasma levels due to reduced metabolic clearance.
Medical Genetics Summaries	RCV000788098	SCV000927096	drug response	Lesinurad response	2019-02-11	criteria provided, single submitter	curation	Lesinurad should be used with caution in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) because of increased exposure and an increased risk of side effects.
Medical Genetics Summaries	RCV000788104	SCV000927102	drug response	Piroxicam response	2019-02-11	criteria provided, single submitter	curation	Individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) have reduced clearance of piroxicam. Because the standard recommended dose of piroxicam may cause abnormally high plasma levels, a dose reduction should be considered for these individuals.
GeneDx	RCV000835752	SCV000977568	likely benign	not provided	2018-03-14	criteria provided, single submitter	clinical testing	This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Labcorp Genetics (formerly Invitae), Labcorp	RCV000835752	SCV001718144	benign	not provided	2024-01-18	criteria provided, single submitter	clinical testing